Please login to the form below

Not currently logged in
Email:
Password:

Keppra

This page shows the latest Keppra news and features for those working in and with pharma, biotech and healthcare.

UCB bags FDA approval for epilepsy drug Briviact

UCB bags FDA approval for epilepsy drug Briviact

Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets. ... Briviact is positioned as a successor to Keppra, which despite

Latest news

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Interview with Roch Doliveux, UCB Interview with Roch Doliveux, UCB

    Though Keppra is now off patent in the US and going off patent in the EU in 2011, it will still be a significant product for many years to come because ... Our largest patent expiries – the trigger to make big changes - were going to occur (and did

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics